Advertisements



Amarin: New Vascepa Prescriptions Grow After REDUCE-IT"s Topline Results

Amarin: New Vascepa Prescriptions Grow After REDUCE-IT"s Topline Results.....»»

Category: topSource: seekingalphaNov 9th, 2018

Why Amarin Shares Are Exploding

Amarin shares absolutely skyrocketed on Monday after the company announced topline results from the Vascepa cardiovascular (CV) outcomes trial, REDUCE-IT. Needless to say, the results were very........»»

Category: blogSource: 247wallstSep 24th, 2018

Amarin Trades Down After Release Of Late-Stage Vascepa Trial Results

Amarin Corporation plc (NASDAQ: AMRN) shares were falling Monday following the presentation of detailed primary results from the the late-stage REDUCE-IT study that evaluated Vascep read more.....»»

Category: blogSource: benzingaNov 12th, 2018

Amarin Corporation PLC (AMRN) CEO John Thero Presents Primary REDUCE-IT Trial Results Following Presentation at 2018 Scientific Sessions of American Heart Association Conference Call (Transcript)

Amarin Corporation PLC (AMRN) CEO John Thero Presents Primary REDUCE-IT Trial Results Following Presentation at 2018 Scientific Sessions of American Heart Association Conference Call (Transcript).....»»

Category: topSource: seekingalphaNov 13th, 2018

Amarin Goes From Solid To Speculative After Full REDUCE-IT Trial Results Released

Amarin Goes From Solid To Speculative After Full REDUCE-IT Trial Results Released.....»»

Category: topSource: seekingalphaNov 12th, 2018

Amarin's REDUCE-IT Trial: Something Fishy? - Seeking Alpha

STATAmarin's REDUCE-IT Trial: Something Fishy?Seeking AlphaAMRN provided an update on the REDUCE-IT trial of Vascepa; the NEJM provided an online article a.....»»

Category: topSource: googlenewsNov 11th, 2018

Amarin"s Stock Soars as Fish Oil Drug Lowers Heart Risks

Amarin (AMRN) shares soar on positive results from a cardiovascular outcomes study on Vascepa. Shares of Amarin Corporation p.....»»

Category: personnelSource: nytSep 27th, 2018

42 Stocks Moving In Monday"s Mid-Day Session

Gainers Amarin Corporation plc (NASDAQ: AMRN) shares jumped 232.4 percent to $9.94 after the company's REDUCE-IT cardiovascular study of Vascepa in LDL-C patients met its primary endpoint. read more.....»»

Category: blogSource: benzingaSep 24th, 2018

Amarin"s REDUCE-IT study on-track to report results before end of September

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 26th, 2018

Amarin Reports Second Quarter 2018 Financial Results and Provides Update on Operations

REDUCE-IT™ Study On-Track for Reporting Top-Line Results by the End of September 2018 Management to.....»»

Category: earningsSource: benzingaAug 1st, 2018

Amarin Reports First Quarter 2018 Financial Results and Provides Update on Operations

REDUCE-IT Study On-Track for Reporting Top-Line Results.....»»

Category: earningsSource: benzingaMay 2nd, 2018

Amarin: Waiting For REDUCE-IT Results

Amarin: Waiting For REDUCE-IT Results.....»»

Category: topSource: seekingalphaApr 11th, 2018

SpaceX wins approval to deploy more than 7,500 satellites

Elon Musk’s SpaceX won permission to deploy more than 7,000 satellites, far more than all operating spacecraft currently aloft, from U.S. regulators who also moved to reduce a growing risk from space debris as skies grow more crowded......»»

Category: topSource: moneycentralNov 15th, 2018

SpaceX wins approval to deploy more than 7,500 satellites

Elon Musk’s SpaceX won permission to deploy more than 7,000 satellites, far more than all operating spacecraft currently aloft, from U.S. regulators who also moved to reduce a growing risk from space debris as skies grow more crowded......»»

Category: topSource: moneycentralNov 15th, 2018

Musk"s SpaceX wins FCC approval to deploy 7,518 satellites

Elon Musk’s SpaceX won permission to deploy more than 7,000 satellites, far more than all operating spacecraft currently aloft, from U.S. regulators who also moved to reduce a growing risk from space debris as skies grow more crowded......»»

Category: topSource: moneycentralNov 15th, 2018

Amarin: 85% Of Doctors Polled At AHA Conference Intend To Prescribe Vascepa

Amarin: 85% Of Doctors Polled At AHA Conference Intend To Prescribe Vascepa.....»»

Category: topSource: seekingalphaNov 14th, 2018

Amarin CEO believes Vascepa well positioned to help "millions of patients"

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallNov 12th, 2018

Amarin"s REDUCE-IT Trial: Something Fishy?

Amarin"s REDUCE-IT Trial: Something Fishy?.....»»

Category: topSource: seekingalphaNov 11th, 2018

U.S. Global Investors" (GROW) CEO Frank Holmes on Q1 2019 Results - Earnings Call Transcript

U.S. Global Investors" (GROW) CEO Frank Holmes on Q1 2019 Results - Earnings Call Transcript.....»»

Category: topSource: seekingalphaNov 9th, 2018

U.S. Global Investors Reports Financial Results for the First Quarter of 2019 Fiscal Year

SAN ANTONIO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- U.S. Global Investors, Inc. (NASDAQ:GROW) (the "Company"), a boutique registered investment advisory firm with longstanding experience in global markets and specialized sectors, toda.....»»

Category: earningsSource: benzingaNov 8th, 2018

Postelection Stock Rally Extends Into Asia

The results of the midterms helped reduce some fears about trade tensions, rising U.S. interest rates and the potential for U.S. economic growth to slow......»»

Category: asiaSource: wsjNov 8th, 2018